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Ivermectin is a widely used drug for the treatment and control
of severalneglected tropicaldiseases.1Thedrughasanexcellent
safety profile, with more than 2.5 billion doses distributed in the
last 30 years, and its potential to reducemalaria transmission by
killingmosquitoes is under evaluation in several trials around the
world.2 Ivermectin inhibits the invitro replicationofsomepositive,
single-stranded RNA viruses, namely, dengue virus (DNV),3–5
Zika virus,4,6 yellow fever virus,7,8 and others.4,7,9
Caly et al.10 recently reported that ivermectin is a potent in-
hibitor of the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) replication in vitro.Given thecoronavirusdisease-
19 (COVID-19) pandemic, this has understandably resonated
widely in the global press.11
Caly et al.10 report a 5,000-fold reduction inSARS-CoV-2RNA
levels, compared with those in controls, after infected Vero/
hSLAM cells were incubated for 48 hours with 5 μM ivermectin.
The ivermectin IC50 for the viruswas calculated at approximately
2.5 μM. These concentrations are the equivalent of 4,370 and
2,190 ng/mL, respectively, notably 50- to 100-fold the peak
concentration (Cmax) achieved in plasma after the single dose of
200μg/kg (14mg ina70-kgadult) commonlyused for thecontrol
of onchocerchiasis.12 Pharmacokinetic studies in healthy vol-
unteers have suggested that single doses up to 120 mg of iver-
mectin can be safe andwell tolerated.13 However, even with this
dose, which is 10-fold greater than those approved by the US
Food and Drug Administration, the Cmax values reported were
∼250 ng/mL,13 one order of magnitude lower than effective
in vitro concentrations against SARS-CoV-2.
These findings may seem to discourage follow-up clinical
trials with ivermectin. However, some in vivo effect may be
possible even if efficacious in vitro concentrations are physi-
ologically unattainable. A recent phase III clinical trial in den-
gue patients in Thailand, in which a once-daily dose of 400
μg/kg for 3 days was found to be safe but did not produce any
clinical benefit,14 showed a modest and indirect in vivo effect
against DNV.14 Previous work by Wagstaff et al.5 reported
inhibition atmuchhigher in vitro concentrations (25μM) inDNV-
infected Vero cells. Both pharmacokinetic considerations and
the relatively long incubation period of DNV might explain the
lack of clinical efficacy. Until we have a better understanding of
ivermectin’s antiviral mode of action and of appropriate in vitro
systems for testing, we caution against using findings in Vero
cells as more than a qualitative indicator of potential efficacy.
Very recently, preliminary findings on a potential effect of
hydroxychloroquine combined with azithromycin against
SARS-CoV-2 were widely publicized,15 leading to a surge in
demand and self-medication, which resulted in serious harm
in some cases and a stock shortage that jeopardized drug
availability for other critical conditions for which hydroxy-
chloroquine or chloroquine is the standard of care, that is, vivax
malaria, rheumatoidarthritis, andsystemic lupuserythematosus.
Efficacy claims for hydroxychloroquine against COVID-19 have
been questioned in follow-up trials using similar dosing
regimens,16,17 and we await results of randomized, con-
trolled clinical trials exploring treatment efficacy.
We believe the recent findings regarding ivermectin warrant
rapidly implemented controlled clinical trials to assess its ef-
ficacy against SARS-CoV-2. These trials may open a new field
of research on the potential use of avermectin antiparasitic
drugs, including compounds with an improved pharmacoki-
netic profile, as antivirals.18However, becauseof the following
points, extreme due diligence and regulatory review are
needed before testing ivermectin in severe disease.
First, ivermectin, which targets glutamate-gated chlorine
channels in invertebrates, may cross-target the GABA-gated
chlorine channels present in the mammalian central nervous
system (CNS) and cause neurotoxicity.19 This is normally
prevented by an intact blood–brain barrier (BBB), but in pa-
tientswith a hyperinflammatory state, endothelial permeability
at the BBB may be increased and cause leaking of drugs into
the CNS, potentially causing harm.20,21
Second, boosted antiretrovirals such as lopinavir/ritonavir
and darunavir/cobicistat, which have been widely used against
SARS-CoV-2based on limited evidence, and a number of other
drugs, are potent inhibitors of cytochrome P450 3A4, the main
metabolic pathway for ivermectin. Concurrent use of these
drugs will result in increased systemic exposure to ivermectin.
Furthermore, ritonavir and cobicistat can readily inhibit one of
the main efflux pumps in the BBB, P-glycoprotein, further fa-
voring neurotoxicity.22,23 However, it is encouraging that a re-
cent analysis of ivermectin-related neurotoxic adverse events
reported to theWHOProgram for International DrugMonitoring
found only one case of 1,668 reports in which concomitant use
of antivirals was associated with neurotoxicity.24
Third, as earlier, available evidence suggests that levels of
ivermectin with meaningful activity against SARS-CoV-2
would not be achieved without extraordinary, potentially
toxic increases in ivermectin dosing levels in humans. How-
ever, evidence from animal models showing up to 3-fold
higher levels in pulmonary tissue than in plasma 1 week after
oral dosing leaves the door open for further research, in par-
ticular for the treatment of respiratory viruses.25,26
The discovery of ivermectin’s activity against SARS-CoV-2
gives reason for hope, but off-label and compassionate use
requires careful risk–benefit considerations,27 especially in
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critically ill patients. A path to consider is evaluation first of
impacts on virologic outcomes in uncomplicated, low-risk
patients early in the course of the disease. Well-conducted
clinical trials informed by robust pharmacokinetic models
should be considered to validate the impact before the use of
ivermectin to treat SARS-CoV-2 is implemented.
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